Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2002 (First Quarter of Fiscal Year 2003)
Business Overview: McKesson operates through three primary segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Information Solutions. The company is a leading provider of healthcare products and services, including pharmaceutical distribution, medical-surgical supplies, and healthcare information technology.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2003 (Ended June 30, 2002) | Q1 2002 (Ended June 30, 2001) |
|---|---|---|
| Revenues | $13,628.0 | $11,656.3 |
| Gross Profit | $752.5 | $660.7 |
| Operating Income | $203.8 | $140.4 |
| Net Income | $117.3 | $105.4 |
| Diluted EPS | $0.39 | $0.36 |
| Cash and Equivalents | $289.8 | $230.3 |
| Total Debt (Current + Long-Term) | $1,428.1 | N/A (Not explicitly aggregated in text) |
| Net Cash Used by Operating Activities | $(203.0) | $(394.4) |
Liquidity: Operating working capital increased to $3,650.8 million from $3,288.2 million. The debt-to-capital ratio stood at 25.0%, well below the 56.5% covenant limit.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 17% year-over-year, driven primarily by the Pharmaceutical Solutions segment (18% growth), which accounts for over 92% of total revenue. Growth was attributed to market expansion, new customer agreements, and increased drug utilization.
- Profitability: Net income rose 11% to $117.3 million. Pro forma net income (excluding special charges) increased 39% to $125.3 million, reflecting margin expansion in the Pharmaceutical segment and improved performance in Information Solutions.
- Cash Flow: Net cash used by operating activities improved significantly, decreasing from a use of $394.4 million in the prior year to $203.0 million. This improvement was due to better inventory management and the absence of a large trade receivable sale that occurred in the prior year.
- Special Charges: Pre-tax special charges decreased to $12.3 million from $23.6 million in the prior year. The prior year included an $18.4 million loss on the sale of businesses, which was not present in the current quarter.
Guidance, Outlook, and Risks
Management Commentary: Management expects U.S. pharmaceutical distribution growth in the second quarter of 2003 to be near the projected market growth rate of the low-teens. The company is re-evaluating restructuring plans for its Medical-Surgical distribution network, with a revised plan expected by the second quarter of 2003.
Acquisitions and Investments:
- Formed a joint venture, Verispan, L.L.C., with Quintiles Transnational Corporation (46% equity interest).
- Completed the acquisition of 98.1% of A.L.I. Technologies Inc. for approximately $350 million (cash tender offer less cash acquired) to expand medical imaging solutions.
Risks and Contingencies:
- Litigation: Ongoing securities litigation related to the 1999 restatement of financial statements due to accounting improprieties at HBO & Company. Management states it is not feasible to predict the outcome or potential loss range, though a settlement could have a material adverse impact.
- Restructuring: Ongoing restructuring activities involve approximately 985 employee terminations and the closure of 30 distribution centers. Final costs may vary based on the re-evaluation of the Medical-Surgical segment plan.
- Market Risks: Exposure to changes in healthcare reimbursement, manufacturer pricing policies, and customer payment defaults.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of the 17% revenue growth, particularly the portion attributed to "Sales to Customers' Warehouses" which have lower margins.
- Litigation Exposure: Monitor the status of the HBOC securities litigation, as the potential liability is undefined and could materially impact future financials.
- Restructuring Costs: Track the final costs associated with the Medical-Surgical distribution center closures, as the company is currently re-evaluating the plan and previously recorded charges may be adjusted.
- Working Capital: Observe the trend in operating working capital ($3.65 billion), which is highly sensitive to inventory purchase patterns and seasonal demand in the pharmaceutical distribution business.
- Acquisition Integration: Assess the integration and valuation of the A.L.I. Technologies acquisition, where a substantial portion of the purchase price is expected to be allocated to goodwill.